Pancreatic cancer remains a significant challenge, with surgery being a cornerstone of curative treatment. In Mexico, it is one of the most aggressive tumors, ranking as the seventh leading cause of cancer death, with approximately 7,000 new cases annually and a mortality rate exceeding 90% five years after diagnosis. The incidence is 3.9 cases per 100,000 inhabitants, and it is most common in people aged 50 to 69.
Pancreatic surgery is complex and associated with higher rates of morbidity and mortality compared to other abdominal surgeries. Over the past decade, the introduction of new technologies, such as minimally invasive approaches, improvements in multimodal treatments, advances in anesthesia and perioperative care, and better management of complications, have collectively improved patient outcomes after pancreatic surgery.

In particular, the adoption of Enhanced Recovery After Surgery (ERAS) recommendations has reduced hospital stays and improved recovery times, as well as postoperative outcomes, in order to employ opioid-sparing multimodal anesthesia, as well as hemodynamic management, goal-guided fluids, optimal therapeutic central glucose levels after surgical injury, as well as blood gas values for adjusting mechanical ventilation, in order to assess early extubation.